Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavilermide in Dry Eye (MIM-728)
NCT03925727Phase 3Completed
- Sponsor
- Mimetogen Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tavilermide in dry eye disease (DED) (3 arms), sponsored by Mimetogen Pharmaceuticals. Primary endpoints: Change From Baseline in Eye Dryness Score as Measured by the Visual Analog Scale (VAS) at Day 85 and Change From Baseline in Total Corneal Fluorescein Staining as Measured by the NEI Scale at Day 85. Started Mar 2019; status: completed.
02
Drugs
tavilermide
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03925727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925727.